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Helping cancer patients quit 
smoking using brief advice based on 
risk communication: A randomized 
controlled trial
William H. C. Li1, M. P. Wang  1, K. Y. Ho1, Katherine K. W. Lam1, Derek Y. T. Cheung1, Yannes 
T. Y. Cheung1, T. H. LAM2 & Sophia S. C. CHAN1
This randomized controlled trial aimed to examine the effectiveness of a smoking cessation 
intervention using a risk communication approach. A total of 528 smoking cancer patients were 
randomly allocated either into an intervention group (n = 268) to receive brief advice based on risk 
communication by a nurse counselor or a control group (n = 260) to receive standard care. Subjects 
in both groups received a smoking cessation booklet. Patient follow-ups were at 1 week and at 1, 3, 
6, 9 and 12 months. No significant differences were found in self-reported point-prevalence 7-day 
abstinence between the intervention and control groups at 6 months (15.7% vs 16.5%; OR 0.94, 95% 
CI 0.59–1.50). The rate of at least 50% self-reported reduction of smoking at 6 months, was higher in 
the intervention group than in the control group (16.8% vs 12.3%; OR 1.43, 95% CI 0.88–2.35). The 
biochemically validated quit rate at the 6-month follow-up was higher in the intervention group than in 
the control group (5.2% vs 3.8%; OR 1.38, 95% CI 0.60–3.16). These data suggest that advice based on 
risk communication was not effective for quitting but improved the rate of smoking reduction among 
smoking cancer patients.
Tobacco smoking causes many types of cancer, including cancer of the lung, larynx, oesophagus, stomach, liver, 
pancreas, kidney, ureter, bladder and colo-rectum, as well as acute myeloid leukaemia1. Although recent advances 
in cancer treatment have dramatically improved the survival rate, cancer patients who continue smoking bear 
extra risks in terms of all-cause mortality as well as reduced treatment effectiveness and survival time2. Smoking 
could also lower the efficacy of cancer treatment3,4 and add to the risk of post-treatment side effects5. On the 
contrary, there is evidence that cancer patients who quit smoking could reduce the risk of disease advancement6, 
improve prognosis, minimize adverse treatment-related effects and promote quality of life7. Given the detrimental 
effects of smoking and the beneficial effects of cigarette smoking cessation, it is essential for healthcare profession-
als to help cancer patients quit smoking.
Smokers who had been diagnosed with cancer attended to out-patient clinics present an excellent ‘teachable 
moment’ for smoking cessation interventions, as it provides a valuable opportunity for them to stop smoking 
cessation to improve their health8,9. Healthcare professionals can also take this golden opportunity to promote 
smoking cessation while they are waiting for medical consultation. However, cigarette smoking is addictive and 
quitting is very difficult, with a high rate of relapse, particularly among those chronic patients with high nicotine 
dependency10,11. Previous studies showed that about one third of cancer patients in Western countries and almost 
50% smokers with lung cancer in USA continued to smoke after receiving a cancer diagnosis12–15. Our recent 
study found that approximately 14% of patients continued smoking after receiving a cancer diagnosis16. Many 
cancer patients who continued smoking had misconceptions that a moderate amount, such as half a pack of cig-
arettes per day, might not be detrimental to their health16. Some smokers said that it was too late to stop smoking 
as their cancer had reached a later stage16. Therefore, it is vital for healthcare professionals to design smoking ces-
sation interventions that use strong warning to clearly communicate the risk of continued smoking to this group 
as a strategy to enhance their motivation to quit.
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Theoretical framework
According the Theory of Planned Behaviors, smokers with positive beliefs in attitudes and subjective norms that 
contribute to stronger intention in quitting will be more likely to quit smoking17. Our intervention therefore 
aimed to change the patients’ attitudes and their subjective norms through risk communication, which was used 
in a previous study, showing a 24% self-reported quit rate at 6 months in lung cancer patients18. To guide the risk 
communication, a core construct of the Transtheoretical Model, named decisional balance that emphasizes the 
importance of balancing the pros and cons of a behavioral change19, was applied. Individuals who consider that 
the cons outweighs the benefits, are more like to continue smoking. Whereas those who perceive greater bene-
fits from quitting smoking are more motivated to change. Accordingly, during the intervention, patients were 
informed the advantages of quitting smoking and drawbacks of not quitting with regard to cancer.
Behavioural intervention has been shown to be helpful in improving cessation rates in smoking cancer patients 
in several randomized controlled trials (RCTs). In head and neck cancer patients, significant differences were 
shown in a behavioural intervention group compared with a usual care group (47% vs. 31%; n = 184, p = 0.05) 
at 6-month follow-up20. Another RCT showed that, compared with those given only standard care, hospitalized 
cancer patients given behavioural intervention had a higher quit rates (21% vs. 14%, n = 28)21. Wakefield et al. 
applied behavioural intervention in an RCT to help patients with mixed cancer sites and demonstrated enhanced 
smoking cessation (29% vs. 18%; n = 137, p = 0.32)22. However, these RCTs were limited by small sample size and 
no RCTs have been conducted on Chinese cancer patients who smoke in Hong Kong and elsewhere.
The present RCT with a large sample size aimed to study the effectiveness of a face-to-face individualized brief 
risk communication to encourage patients with cancer to stop smoking. We hypothesized that participants in the 
intervention group would (i) have a higher smoking cessation rates by self-reporting and biochemical validation 
and (ii) have a higher self-reported rate of having reduced daily cigarette consumption by at least 50%.
Methods
Ethical Review. This study was approved by the Institutional Review Board of the University of Hong Kong 
and the Hospital Authority of Hong Kong West Cluster (Reference: UW 12-113) and was registered on the 
Clinical Controlled Trials registry as NCT01685723. Eligible subjects were invited to participate in the study after 
being informed of its purpose. They were informed that their participation was voluntary and without prejudice, 
and given the opportunity to refuse to participate. Written informed consent was obtained from all eligible sub-
jects prior to randomization and all the research procedures were in compliance with the Helsinki.
Study Participants. Smokers who attended medical follow-up visits at outpatient clinics of the Clinical 
Oncology Departments of five major hospitals in different regions of Hong Kong and who met the inclusion crite-
ria were invited to participate. The inclusion criteria were subjects who (a) had smoked at least weekly in the past 
6 months; (b) had been diagnosed with cancer not limited to smoking-induced cancers; (c) were in any of the can-
cer stages 0, I, II, III, or IV; and (d) aged 18 above and able to communicate in Cantonese. Subjects were excluded 
if they had already participated in other smoking cessation programs, had unstable medical conditions, or had 
a poor cognitive state or mental illness as advised by the doctor in charge and noted on their medical records.
Sample Size. In a previous study which examined the effectiveness of an intervention based on risk com-
munication approach in motivating 137 smoking patients with mixed cancer sites to quit, the self-reported 7-day 
point prevalence quit rate at the 6-month follow-up was 29% for the intervention group and 18% for the control 
group22. To detect a statistical difference at the two-sided 5% significance level and a power of 80%, 233 subjects 
were required for each group. Based on the 15% subject attrition rate at the 6-month follow-up that was experi-
enced in a local RCT on smoking cessation intervention for cardiac patients23, 548 subjects were required in total.
Interventions. The intervention proposed is a behavioural intervention as it was repeatedly delivered in 
order to initiate behavioural change24. In particular, subjects received face-to-face individualized brief advice 
based on risk communication for 15–30 minutes from the smoking cessation counselors, followed by exhaled 
carbon monoxide level assessment measured by using smokerlyzer (Bedfont® Scientific, Harrietsham, UK). 
Counselors delivered brief advice based on a specifically-designed risk communication leaflet that warns about 
the risks of continued smoking for subjects’ cancer treatment and prognosis7. A high intensity counseling session 
(>30 minutes) may be able to boost the quit rate25, but is not practicable or feasible in busy clinical settings. In 
addition, subjects may lose patience while they are waiting for medical consultation in out-patient clinics. Thus 
the intervention was kept short (within 15–30 minutes). The risk communication component focused on the 
relationships between smoking and cancer diagnosis, treatment and prognosis as a trigger to think about quitting. 
Subjects in the experimental group also received a booster intervention via telephone during follow-up at 1 week. 
The booster intervention aimed to assess the progress of and barriers to the subjects’ action plans and identifying 
individual difficulties and facilitators towards quitting. To support the subjects to quit smoking, the counselors 
would provide information on how to handle withdrawal symptoms. However, nicotine replacement therapy 
were not provided in this study as it may not be appropriate for patients with some diseases, particularly those 
undergoing medical treatment23. In addition, the acceptance of and adherence to such therapy is low even among 
Chinese smokers who want to quit26.
Subjects in the control group received only standard care without risk communication, but had the same 
follow-up sections as the intervention group to receive diseases support. Subjects in both groups received a 
generic standard self-help smoking cessation booklet.
Study Design. This was a single-blinded simple individual RCT. Smoking cessation counselors approached 
the patients at the oncology outpatient clinic and queried their smoking and cancer diagnosis status. A list of 
computer-based random numbers was generated by SPSS software for each hospital to allocate consented subjects 
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into groups. Counselors opened a serially-numbered sealed-opaque envelope to ensure each subject’s allocation 
was concealed after baseline survey. Such a masking procedure avoids bias in completing the baseline question-
naire and the design follows the recommendations of CONSORT’s Statements to guide randomized controlled 
studies (http://www.consort-statement.org/).
Study Assessments and Outcomes. The primary outcome was self-reported 7-day point-prevalence 
smoking abstinence at 6-month follow-up. The secondary outcomes include self-reported 7-day point-prevalence 
smoking abstinence at 12-month follow-up, biochemically validated quit rate at 6-month follow-up and percent-
age of patients reduced smoking by at least 50% at 6- and 12-month follow-up compared to baseline.
Demographics and Smoking Characteristics. Baseline data included smoking history, demographic, 
socioeconomic and clinical characteristics obtained from each subject using a structured questionnaire adminis-
tered by a trained nurse counselor. The content of the structured questionnaire included smoking-related infor-
mation, such as daily cigarette consumption, nicotine dependency as assessed by the Fagerstrom test27, the stage 
of readiness to quit smoking19 and previous quit attempts.
Data Collection. The data collection period including the subject recruitment and follow-up were between 
September 2012 and March 2015. For both groups, all the consecutive follow-ups at 1 week and 1, 3, 6, 9 and 12 
months were conducted by trained nurse counselors via telephone. A structured questionnaire was adopted to 
assess subjects’ smoking and quitting history, risk perceptions of smoking28, illness perception29, intention to quit 
smoking (stage of readiness to quit)10 and self-efficacy to quit smoking30.
Subjects who quit smoking successfully at 6 months were invited to take the biochemical validation test, which 
comprised measurement of cotinine in saliva (<115 ng/mL NicAlert strips (www.nymox.com)31 and an exhaled 
carbon monoxide test (<4 ppm to confirm quitting or <9 ppm for smoking reduction)32. Subjects were reim-
bursed for travel to the biochemical validation test and lucky draws (cash incentives) were offered to boost the 
response rates for the follow-ups. Ten subjects from the intervention group who had not quit were invited for 
a recorded 10- to 20-minute individual process evaluation in the form of face-to-face interviews by research 
assistants at 12-month follow-up. They were asked two open-ended questions such as “What do you think of the 
intervention leaflet? Was it useful or not?” and “Did you reduce your smoking after joining our program?” The 
responses were recorded and translated verbatim for analysis.
Statistical Analysis. Quantitative data were analysed using the Statistical Package for Social Science (SPSS 
Inc., Chicago, IL, USA) version 23.0 for Windows. Baseline demographic characteristics of subjects between 
intervention and control group were compared using Chi-square test or Fisher’s exact test for categorical vari-
ables and t-test for continuous variables. The effect on smoking cessation at 6 and 12 months was compared by 
unadjusted odds ratios (ORs) using logistic regression. Predictors of abstinence at 6 and 12 months were analysed 
by multivariable logistic regression to yield the adjusted ORs. Intention-to-treat analysis33 was used in this study 
with all subjects (N = 528) were included in the analysis and all non-responses were treated as non-quitters. The 
significance level of all analyses was set at 5%. Qualitative data from the process evaluation were tape-recorded 
and transcribed verbatim. Data were summarized to evaluate the effect of the intervention as perceived by the 
participating subjects.
Results
Baseline Study. Of the 43,539 subjects screened at the oncology units during the study period, 1425 (3.3%) 
subjects were eligible. However, 897 patients either showed no interest in joining the study or were unavailable 
for the upcoming interventions. The remaining 528 patients were randomly assigned to the intervention group 
(n = 268) and control group (n = 260). The retention rates for the intervention and control groups were 189/268 
(70.5%) and 180/260 (69.2%) at 6 months, respectively. The retention rates were 156/268(58.2%) and 149/260 
(57.3%) for intervention and control groups, respectively at the 12-month follow-up. The principle of intention-
to-treat was applied and the sample size included in the final analysis was 528. The Consolidation of Standards for 
Reporting Trials (CONSORT) flowchart in Fig. 1 indicated the process of the study and no adverse effects were 
reported throughout the trial.
In Table 1, the average age of the 528 subjects was 58.9 ± 12.3 years. About one-third of the subjects were 
employed (n = 201, 38.1%) while 38.9% of them had retired (n = 205). Most were pre-contemplating quitting 
smoking (72.0%, n = 380) and smoked 12.5 ± 8.0 cigarettes daily. They smoked for 42.0 ± 13.2 years on average, 
with mild to moderate nicotine dependence (scored 3.1 ± 2.2). Over 80% of the cancers had been first diagnosed 
at the beginning of the program in both the intervention and control group subjects and the distributions of can-
cer locations among the groups were similar. About 40% of the subjects from both groups perceived their health 
status as fair. Except for the distribution in education attainment (p = 0.02), no statistically significant differences 
were found between the intervention and control groups in the demographic characteristics at baseline.
Intervention outcomes. The outcomes for effectiveness of the smoking cessation intervention using a risk 
communication approach are shown in Table 2. No statistically significant differences were found in the 7-day 
point-prevalence of smoking abstinence or in self-reported quit attempts at 6 months and 12 months. However, 
the biochemically validated quit rate was higher in the intervention group than in the control group (5.2% vs. 
3.8% at 6 months and 5.6% vs. 4.6% at 12 months) although significance was not reached. Self-reported smoking 
reduction of at least 50% at 6 and 12 months was also higher in the intervention group than in the control group 
(16.8% vs. 12.3%; p = 0.14 at 6 months and 10.4% vs. 9.6%; p = 0.75 at 12 months). There were a total of 47 sub-
jects who had passed away as of the 12-month follow up and there was no significant difference in the mortality 
rate between the intervention and control groups.
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Prediction factors in follow-up periods. In Table 3, logistic regression results indicated that the rates of 
quitting smoking in the intervention group at 6 months were similar in both crude (OR, 0.94; 95% CI, 0.59–1.50) 
and adjusted (AOR, 1.03; 95% CI, 0.63–1.70) models. Similar results were also found in 12 month follow up with 
crude ratio (OR, 0.69; 95% CI, 0.44–1.08) and adjusted models (AOR, 0.75; 95% CI, 0.47–1.20). After adjusting 
for sociodemographic variables at baseline, the results showed that gender did not predict the likelihood of quit-
ting smoking at 6 months (OR, 0.85; 95% CI, 0.42–1.73) and 12 months (OR, 1.03; 95% CI, 0.51–2.08).
Similar null findings were observed for other predictors such as age, education attainment, baseline daily 
cigarette consumption and previous quit attempts.
Process evaluation. There were a total of 10 non-quitters who consented and were interviewed from the inter-
vention group after the trial. Some of them reported that they reduced their smoking because of physical symptoms 
such as suffering from shortness of breath after physical activity. Many thought that because they already suffered 
from cancer so they would like to smoke to relax or ease the side-symptoms of the treatment. Some of them men-
tioned that even non-smokers ultimately die and that therefore there was nothing to be afraid of or worried about 
with regard to smoking. Many of them said that they did read the specifically designed risk communication leaflet 
with regard to cancer and smoking but that they usually put it away afterwards and that it was easy to lose.
Figure 1. The Consolidation of Standards for Reporting Trials (CONSORT) Flowchart.
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Interventionb (n = 268) Controlc (n = 260) P-value
Gender, n (%)
   Male 234 (87.3) 221 (85.0) 0.44
   Female 34 (12.7) 39 (15.0)
Age, mean ± SD 59 ± 12.8 59 ± 11.7 0.70
Site of primary cancera, n (%) 0.19
   Lung 34 (12.7) 23 (8.8)
   Colorectal 51 (19.0) 55 (21.2)
   Prostate, Testicle 22 (8.2) 17 (6.5)
   Liver, Bile duct 28 (10.4) 31 (11.9)
   Stomach, Pancreas, Small intestine 19 (7.1) 12 (4.6)
   Kidney, Bladder 6 (2.2) 7 (2.7)
   Nasopharynx 46 (17.2) 40 (15.4)
   Oral, tongue, Tonsil, Vocal cord 6 (2.2) 8 (3.1)
   Throat, Esophagus, Thyroid 29 (10.8) 24 (9.2)
   Breast 4 (1.5) 17 (6.5)
   Bone, Big cell, Sarcoma, Skin, thigh 5 (1.9) 6 (2.3)
   Lymphoma 10 (3.7) 9 (3.5)
   Cervical, Ovary 2 (0.7) 6 (2.3)
    Nervous system, Neck, Brain 5 (1.9) 2 (0.8)
    Missing 1 (0.4) 3 (1.2)
Educational attainmenta, n (%) 0.02*
   Primary school or below 115 (43.2) 85 (32.7)
   Secondary 137 (51.5) 163 (62.7)
    Tertiary or above 14 (5.3) 9 (3.5)
    Missing 2 (0.7) 3 (1.2)
    Marital status, n (%)
   Single 23 (8.6) 24 (9.2) 0.32
   Married/cohabitation 205 (76.5) 202 (77.7)
   Divorced/separated 34 (12.7) 23 (8.8)
   Widowed 6 (2.2) 11 (4.2)
Employment statusa, n (%)
   Retired 100 (37.3) 105 (40.4) 0.78
   Unemployed 60 (22.4) 59 (22.7)
    Employed 105 (39.2) 96 (36.9)
    Missing 3 (1.1) 0 (0)
Stages of cancer (exclude missing)a, n (%)
   Stage 0, I 36 (13.4) 30 (11.5) 0.58
   Stage II 48 (17.9) 39 (15.0)
   Stage III 39 (14.6) 37 (14.2)
   Stage IV 28 (10.4) 37 (14.2)
    Not identified 112 (41.8) 109 (41.9)
    Missing 5 (1.9) 8 (3.1)
Diagnosis Statusa, n (%)
   First diagnosis 212 (79.1) 215 (82.7) 0.35
    Recurrence 24 (9.0) 18 (6.9)
    Missing 32 (11.9) 27 (10.4)
Previous serious quit attempts for 24 hoursa, n (%) 0.94
   Yes 185 (69.0) 178 (68.5)
    No 83 (31.0) 81 (31.2)
    Missing 0 (0) 1 (0.4)
Stage of readiness to quit, n (%)a 0.41
   Pre-contemplation stage 194 (72.4) 186 (71.5)
   Contemplation stage 33 (12.3) 30 (11.5)
   Preparation stage 33 (12.3) 25 (9.6)
    Action stage 7 (2.6) 13 (5.0)
    Missing 1(0.4) 6 (2.3)
Years of regular smokinga, mean ± SD 42 ± 14.1 42 ± 12.3 0.59
No. of cigarette consumed per day (baseline), mean ± SD 13 ± 7.8 12 ± 8.1 0.55
Fagerstrom Nicotine Dependence Scorea, mean ± SD 3.2 ± 2.2 3.0 ± 2.2 0.39
Table 1. Baseline characteristics of the subjects. aMissing data are excluded. bBrief advice based on risk 
communication. cUsual care.
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Discussion
The present study examined the effectiveness of a brief intervention based on risk communication to help Hong 
Kong Chinese cancer patients quit smoking. To the best of our knowledge, this is the first and largest RCT con-
ducted to evaluate a smoking cessation intervention to help cancer patients quit smoking in Chinese population. 
One strength of the study is that power analysis was used to estimate the sample size, which reduced the chance 
of committing type II error. In addition, a large sample of subjects were recruited from outpatient clinics of five 
major hospitals in different regions of Hong Kong, which enhance the generalizability of the findings.
The results showed that biochemically validated quit rate at the 6-month follow-up was higher in the interven-
tion group than in the control group though it was not statistically significant. However, there was no significant 
difference in the primary outcome, 6-month self-reported 7-day abstinence, between the intervention and control 
groups. About three quarters of the subjects were not prepared to quit and some of them even ignored the smok-
ing cessation advice upon recruitment. There are some possible reasons to explain the non-significant findings. 
First, despite Hong Kong is a westernized city; many people are still subject to the influence of Confucianism, 
especially its associated notion of fatalism16. Some cancer patients might believe that nothing could be done to 
change their fate and hence decided not to quit smoking even after they were told that continued smoking would 
be further detrimental to their health. Second, our previous study showed that most subjects quitted smoking 
following cancer diagnosis16. In general, subjects in the present study were not in the early diagnosis stage but 
already had 5 years in average since the diagnosis of cancer. About 72.9% subjects were in the pre-contemplation 
stage of quitting smoking and most of them were reluctant to quit smoking. If most of the smokers who wanted 
to quit had quit before being recruited in our RCT, the subjects included probably represent the most hard-core 
smokers. Our intervention could be too brief and inadequate to make an impact on such smokers. The results are 
also in-line with some previous reviews indicating that comprehensive intervention might be more effective than 
brief advice to promote smoking cessation34–37. However, providing comprehensive smoking cessation to cancer 
patients is not feasible in Hong Kong busy clinical settings, as in general, it takes more than 30 minutes to imple-
ment. One alternative strategy to enhance the brief intervention effect is to refer and motivate smokers to utilize 
the existing smoking cessation services in Hong Kong, in particular for everyone who needs more counseling. 
We recently conduct a RCT to test the effectiveness of a brief smoking cessation intervention combines different 
components, i.e. brief advice based on the AWARD (ask; warn; advise; refer; and do it again) model, referral 
and follow-ups, among people attending emergency departments. The preliminary results indicated that such 
approach is effective in promoting smoking cessation among people attending emergency departments (7-day 
point prevalence quit rate - Intervention group: 10.4% vs Control group: 6.6%).
Results indicated that self-reported smoking reduction of at least 50% at 6 and 12 months was higher in 




N = 260 P-value
Primary outcome at 6 monthsa
Self-reported 7-day quit rate 42 (15.7) 43 (16.5) 0.79
Secondary outcomea
Self-reported 7-day quit rate
   1 month 43 (16.0) 54 (20.8) 0.16
   3 months 49 (18.3) 45 (17.3) 0.77
   9 months 40 (14.9) 49 (18.8) 0.23
   12 months 40 (14.9) 53 (20.4) 0.10
Biochemically validated quit rate
   6 months 14 (5.2) 10 (3.8) 0.45
Change of stage of readiness between 1- and 6-month
   Decreased 26 (9.7) 18 (6.92) 0.37
   No Change 161 (60.1) 167 (64.2)
   Increased 44 (16.4) 37 (14.2)
Self-reported reduction in daily cigarette consumption ≥50%b
   6 months 45 (16.8) 32 (12.3) 0.14
   12 months 28 (10.4) 25 (9.6) 0.75
At action stage of readiness to quit
   6 months 42 (15.7) 44 (16.9) 0.67
   12 months 37 (13.8) 49 (18.8) 0.12
Quit attempt to abstain smoking for >24 hrs since last assessmentb
   6 months 21 (7.8) 21 (8.1) 1.00
   12 months 20 (7.5) 24 (9.2) 0.35
Table 2. Quit rate, smoking reduction rates and quit attempts in intervention and control groups aBy intention-
to-treat analysis: assume all non-responded follow-up patients as current smokers, who did not make a quit 
attempt over the period and did not change their behavior compared to baseline. bQuitters excluded from 
numerator. cBrief advice based on risk communication. dUsual care.
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reluctant to quit were willing to reduce the number of cigarettes smoked per day. Therefore, another potential 
option would be to help cancer patients who smoke to reduce the number of cigarettes smoked gradually, with 
the ultimate goal of complete cessation. A meta-analysis summarizing 10 studies on quitting at once verse grad-
ually quitting indicated that patients should be allowed to select their own schedules of quitting, such as to quit 
immediately or to reduce the number of cigarettes smoked progressively38. It is anticipated that patients who have 
an opportunity to decide on their own treatment may feel more eager to comply with instructions as a result of 
an increase in autonomy.
Misconceptions about smoking was shown in the risk communication leaflet and such information was 
repeated during telephone counseling. However, subjects in interviews mentioned that the leaflet was easy to 
lose and that its message was not impressive enough. Thus, a digital reminder via a smartphone application might 
be explored as an alternative electronic approach. Many studies have already evaluated the effectiveness of using 
such digital reminders as a form of cessation intervention with positive feedback39–41.
Limitation. This study is limited in that the participation rate for biochemical validation was low (27.6%, 24 
out of 87 at 6 months). Because of the disease and tiredness, many cancer patients who reported quitting showed 
hesitation to come back for biochemical validation even with financial incentive provided. Other methods of 
biochemical validation could be explored to increase the participation rate, such as asking subjects to provide 
samples such as saliva or hair42, or visiting subjects’ homes to conduct the test. Another limitation is that the 
effect size of the intervention in this study was lower than what we expected. Despite the fact that more subjects 
in the experimental group reported smoking reduction of at least 50% than in the control group at both 6- and 
12-month follow-ups, the differences between the two groups were not statistically significant. The results suggest 
that the relationship between the intervention and the outcomes might have been affected by the limited sample 
size. It is quite possible that with a larger sample that difference would be statistically significant.
Implications for Future Practice and Research. The research addressed an important health issue, 
i.e. to help cancer patients quit smoking, which can lower the risk of disease advancement, minimize adverse 
treatment-related effects and improve the prognosis and quality of life of patient. The research is original and it 
helps clarify the effectiveness of a brief smoking cessation intervention to help cancer patients quit. Moreover, 
this study demonstrated the feasibility of implementing smoking cessation intervention in outpatient clinics. The 
outcomes of this research help inform future researchers and policy making on smoking cessation for cancer 
patients and thus have important implications for clinical practice and health significance.
Conclusion
In conclusion, our smoking cessation intervention based on a risk communication approach was not effective in 
helping cancer patients to quit smoking. Adding digital reminders could be a future perspective to improve the 
intervention. In addition, our intervention could be considered as an add-on intervention to existing smoking 
cessation services to increase the risk perception associated with tobacco use among cancer patients.
Variablesa 6-month P-value 12-month P-value
Unadjusted model n = 528 n = 528
Intervention groupb 0.94 (0.59–1.50) 0.79 0.69 (0.44–1.08) 0.10
Control groupc 1.00 1.00
Adjusted modeld n = 515 n = 515
Study group
  Intervention groupb 1.03 (0.63–1.70) 0.90 0.75 (0.47–1.20) 0.22
  Control groupc 1.00 1.00
Sex
  Male 0.85 (0.42–1.73) 0.66 1.03 (0.51–2.08) 0.94
  Female 1.00 1.00
Age 1.01 (0.99–1.03) 0.32 1.01 (0.99–1.04) 0.22
Education
  Primary or below 0.91 (0.27–3.10) 0.88 1.00 (0.30–3.30) 1.00
  Secondary 1.28 (0.40–4.17) 0.68 1.11 (0.35–3.54) 0.85
  Post-secondary 1.00 1.00
Baseline daily cigarette consumption 1.02 (0.99–1.04) 0.30 0.97 (0.94–1.01) 0.09
Baseline past quitting attempt
  Yes 0.79 (0.46–1.34) 0.38 0.73 (0.45–1.19) 0.21
  No 1.00 1.00
Table 3. Factors predicting smoking cessation at 6 and 12 months follow-up. aBy intention-to-treat analysis: 
assume all non-responded follow-up patients as current smokers and they did not made a quit attempt over the 
period and did not change their behaviour compared to baseline. bBrief advice based on risk communication. 
cUsual care. dModel adjusted for all the variables listed.
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